Case Study: Top-10 Pharmaceutical Company achieves identification of $79M+ in underperforming managed-care investments with IntegriChain

Top-10 Pharmaceutical Company - Customer Case Study

Top-10 Pharmaceutical Company engaged IntegriChain to address a perceived disconnect between its contract negotiation and contract analysis functions in Contract Analysis and Administration. The manufacturer believed that contract performance was falling short of expectations and asked IntegriChain to apply its Rational Pricing methodology and software to determine whether pricing investments were optimized.

IntegriChain loaded more than two years of internal administrative data plus third‑party sources into its business tool and analyzed performance for two highly promoted brands across 16 strategic PBMs/HMOs, identifying data gaps and inconsistencies and profiling accounts to set rational prices. The work uncovered non‑performing and marginally performing investments — for one product six accounts (~$26M/year) and for the other four accounts (~$34M/year) — and identified more than $79M in investments underperforming against national and regional benchmarks.